Latest news
CardiNor AS has achieved CE marking according to IVDD for the CardiNor Secretoneurin ELISA assay. We will now expand our distribution network globally and prepare for US market entry.
SN is the only biomarker shown to be associated with biological processes linked to cardiomyocyte handling and has been described as the “missing link biomarker” in cardiovascular disease risk assessment.
Press releases
2022
2021
CardiNor secures NOK12 million to commercialise first secretoneurin (SN) ELISA test
2018
2016
New Data Supports Correlation Between Secretoneurin and Cardiovascular Disease
2015
CardiNor receives USD 0.75M to develop “missing link” CV risk test.
In the media
Unicard, 17.11.2016: (secretoneurin predicts mortality in patients with acute respiratory failure. Article in Norwegian)
Scientific Nordic, 02.10.2015:
Unicard, 12.03.2015:
VG, 27.09.2015: